Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

Pharmala Biotech Holdings  / Equity Bottom-Up

<ul><li>Strategic pivot to a capital-light, IP-licensing model. PharmAla is deliberately shifting toward a capital-light model in which partners fund development while the company contributes its IP.</li><li>Management cites the Restora SPV spin-out of APA-01, repositioned as a neurology, non-controlled-substance asset, and the proposed US licensing transaction for ALA-002 with Jupiter Neurosciences as transformational.</li><li>If completed, the combined licensing transactions could generate ~US$4 million in value, substantially exceeding management’s current expectation of ~$2 million in annual product sales across Australia and international markets on a go-forward basis.</li></ul>

Strategic pivot to a capital-light, IP-licensing model. PharmAla is deliberately shifting toward a capital-light model in which partners fund development while the company contributes its IP.Management cites the Restora SPV spin-out of APA-01, repositioned as a neurology, non-controlled-substance asset, and the proposed US licensing transaction for ALA-002 with Jupiter Neurosciences as transformational.If completed, the combined licensing transactions could generate ~US$4 million in value, substantially exceeding management’s current expectation of ~$2 million in annual product sales across Australia and international markets on a go-forward basis.

MDMA: From MDMA Supply Chain to Data Advantage

<ul><li>Restora Neurosciences SPV housing APA-01. PharmAla entered a definitive agreement with CRO Diteba and its parent company Aluvaris through the formation of Restora Neurosciences, a 50/50 Special Purpose Vehicle (SPV) with Aluvaris and Diteba to develop its patented non-controlled molecule, APA-01. </li><li>Under the terms of the agreement, PharmAla contributes the preclinical asset and global IP, Aluvaris funds the vehicle by raising a ~$2.5-million threshold, and Diteba runs the bioanalytical and IND work.</li><li>The SPV must file its first IND within 36 months of funding, with failure reverting the IP to PharmAla. </li></ul>

Restora Neurosciences SPV housing APA-01. PharmAla entered a definitive agreement with CRO Diteba and its parent company Aluvaris through the formation of Restora Neurosciences, a 50/50 Special Purpose Vehicle (SPV) with Aluvaris and Diteba to develop its patented non-controlled molecule, APA-01. Under the terms of the agreement, PharmAla contributes the preclinical asset and global IP, Aluvaris funds the vehicle by raising a ~$2.5-million threshold, and Diteba runs the bioanalytical and IND work.The SPV must file its first IND within 36 months of funding, with failure reverting the IP to PharmAla. 

PharmAla Biotech Holding: The Pathway to Unlocking Pipeline Value Early

<ul><li>FDA’s first-ever priority vouchers send out positive signals for psychedelics.</li><li>Following up on our podcast discussion with Kadysh in June about the FDA’s proposed reforms, including the idea of a national priority voucher program, he highlighted the recent award of the first-ever priority vouchers to nine products, which included ketamine (a psychedelic-like compound) for US manufacturing.</li><li>This means that anyone who applies to the FDA to manufacture ketamine in the US (currently approved for the treatment of treatment-resistant depression under the brand Spravato®) gets an “incredibly aggressive” two-month review timeline. </li></ul>

FDA’s first-ever priority vouchers send out positive signals for psychedelics.Following up on our podcast discussion with Kadysh in June about the FDA’s proposed reforms, including the idea of a national priority voucher program, he highlighted the recent award of the first-ever priority vouchers to nine products, which included ketamine (a psychedelic-like compound) for US manufacturing.This means that anyone who applies to the FDA to manufacture ketamine in the US (currently approved for the treatment of treatment-resistant depression under the brand Spravato®) gets an “incredibly aggressive” two-month review timeline. 

Psychedelics, the FDA, and PharmAla's Strategic Approach Post-Lykos CRL

Canada

Pharmala Biotech Holdings Inc. operates as a biotech company. The Company focuses on domestic research, development, and manufacturing of clinical-grade MDMA and novel MDXX compounds in service to the scientific research community. Pharmala Biotech Holdings serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pharmala Biotech Holdings (MDMA CN)

MDMA: From MDMA Supply Chain to Data Advantage

PharmAla is deliberately shifting toward a capital-light model in which partners fund development while the company contributes its IP.

Water Tower Research

PharmAla Biotech Holding: The Pathway to Unlocking Pipeline Value Early

Kadysh stressed that partner execution and trust outweigh headline economics, citing the successful Cortexa JV with Vitura Health as precedent.

Water Tower Research

Psychedelics, the FDA, and PharmAla's Strategic Approach Post-Lykos CRL

In Kadysh’s view, this clearly signals FDA recognition of an unmet need, reflected by the rapid growth in the demand for Spravato® seen in the...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)